Harpoon Therapeutics, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)

This study is testing a new drug called HPN328, both alone and in combination with other cancer drugs, for people with advanced cancers that have a specific marker called DLL3. The main goals are to find safe and effective doses and to see how well the treatments work. The trial …

This is an early-stage study to test the safety of a new drug called HPN217 (or MK-4002) for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will give increasing doses to about 100 participants to find the highest dose that i…